We are live on ! Find out more
OPPM

Opus Point Partners Management Portfolio holdings

AUM $55.3M Turnover 18.46%
1-Year Est. Return 7.48%
This Fund
S&P 500
This Quarter Est. Return
-15.77%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$181M
AUM Growth
+$54.8M
Cap. Flow
+$26.4M
Cap. Flow %
14.57%
Top 10 Hldgs %
55.68%
Holding
69
New
12
Increased
29
Reduced
12
Closed
12
Avg Time Held Equity + Options
0.5 years
Top 10 Avg Time Held Equity + Options
0.2 years
Top 20 Avg Time Held Equity + Options
0.5 years
Avg Time Held Equity only
0.6 years
Top 10 Avg Time Held Equity only
0.2 years
Top 20 Avg Time Held Equity only
0.6 years

Top Buys

Rank Stock Value
1
IBB icon
iShares Biotechnology ETF
IBB
+$7.2M
2
AGIO icon
Agios Pharmaceuticals
AGIO
+$4.5M
3
MDVN
MEDIVATION, INC.
MDVN
+$2.46M
4
BMY icon
Bristol-Myers Squibb
BMY
+$2.28M
5
MRK icon
Merck
MRK
+$2.28M

Top Sells

Rank Stock Value
1
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$5.34M
2
BIB icon
ProShares Ultra NASDAQ Biotechnology
BIB
+$1.78M
3
TSRO
TESARO, Inc.
TSRO
+$1.76M
4
PCRX icon
Pacira BioSciences
PCRX
+$1.59M
5
ESPR icon
Esperion Therapeutics
ESPR
+$1.23M

Sector Composition

Rank Sector Weight
1 Healthcare 59.5%
2 Miscellaneous 40.37%
3 Financials 0.14%
4 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
LABU icon
51
Direxion Daily S&P Biotech Bull 3X ETF
LABU
$524M
$241K 0.13%
+186
New +$568K
2015 Q3
0 quarters
TLPH icon
52
Talphera
TLPH
$56.6M
$176K 0.1%
2,887
-2,111
-42% -$174K
2014 Q4
3 quarters
KPTI icon
53
Karyopharm Therapeutics
KPTI
$7.84M
$155K 0.09%
+983
New +$263K
2015 Q3
0 quarters
ASMB icon
54
Assembly Biosciences
ASMB
$408M
$143K 0.08%
1,250
-4,167
-77% -$733K
2015 Q1
2 quarters
XNPT
55
DELISTED
XENOPORT, INC.
XNPT
$139K 0.08%
40,000
-90,000
-69% -$568K
2014 Q4
3 quarters
LAB icon
56
Standard BioTools
LAB
$253M
$122K 0.07%
+15,000
New +$236K
2015 Q3
0 quarters
ESPR icon
57
DELISTED
Esperion Therapeutics
ESPR
– –
-15,000
Closed -$1.23M –
RARE icon
58
Ultragenyx Pharmaceutical
RARE
$1.45B
– –
-9,000
Closed -$922K –
NEPT
59
DELISTED
Neptune Wellness Solutions Inc. Ordinary Shares
NEPT
– –
0
– -$1K
2015 Q1
2 quarters
ALBO
60
DELISTED
Albireo Pharma Inc
ALBO
– –
-21,667
Closed -$670K –
ARRY icon
61
CALL
DELISTED
Array Biopharma Inc
ARRY
– –
-2,000
Closed -$135K –
TSRO
62
DELISTED
TESARO, Inc.
TSRO
– –
-30,000
Closed -$1.76M –
JUNO
63
DELISTED
Juno Therapeutics, Inc.
JUNO
– –
-5,000
Closed -$267K –
JUNO
64
PUT
DELISTED
Juno Therapeutics, Inc.
JUNO
– –
-50
Closed -$49K –
OCRX
65
DELISTED
Ocera Therapeutics, Inc.
OCRX
– –
-186,573
Closed -$709K –
RLYP
66
DELISTED
RELYPSA INC COM
RLYP
– –
-18,000
Closed -$596K –
RCPT
67
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
– –
-28,124
Closed -$5.34M –
KBIO
68
DELISTED
KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE)
KBIO
– –
-93,308
Closed -$358K –
1 2
3

Similar funds

KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return
PGA
Premia Global Advisors Coral Gables, Florida $57.9M AUM 2.91% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return
SCG
Saban Capital Group Los Angeles, California $59.5M AUM 3.83% 1-Year Est. Return
TCMV
Technology Crossover Management VI Menlo Park, California $59.6M AUM 18.81% 1-Year Est. Return
FCM
Farmstead Capital Management Ridgewood, New Jersey $49M AUM 10.57% 1-Year Est. Return
DP
DW Partners New York $62.3M AUM 25.52% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return

Opus Point Partners Management's Q3 2015 Portfolio in Review

As of Q3 2015, Opus Point Partners Management held 69 positions worth $181M, up 43% from $126M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Opus Point Partners Management deployed $26.4M of net new capital in Q3 2015, opening 12 new positions and adding to 29 existing holdings. Its largest new stake was iShares Biotechnology ETF: 60,000 shares worth $6.07M.

By sector, the portfolio is most concentrated in Healthcare at 59% of assets, down from 83% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was ProShares Ultra NASDAQ Biotechnology, an estimated $1.78M trimmed.

  • Opus Point Partners Management's largest Q3 2015 buy was iShares Biotechnology ETF: 60,000 shares worth $6.07M.
  • Opus Point Partners Management added most to MEDIVATION, INC. in Q3 2015, an estimated $2.46M increase.
  • Opus Point Partners Management's biggest Q3 2015 reduction was ProShares Ultra NASDAQ Biotechnology, cutting an estimated $1.78M.
  • Opus Point Partners Management fully exited RECEPTOS INC COM STK (DE) in Q3 2015, selling an estimated $5.34M.
  • Opus Point Partners Management's ten largest holdings make up 56% of its $181M portfolio in Q3 2015.
  • Opus Point Partners Management opened 12 new positions and closed 12 in Q3 2015.
  • Opus Point Partners Management's portfolio value rose 43% quarter-over-quarter to $181M.

Based on Opus Point Partners Management's 13F filing for Q3 2015, filed 16 Nov 2015.